Tearsheet

ADMA Biologics (ADMA)

Market Price (12/29/2025): $19.1 | Market Cap: $4.6 Bil
Sector: Health Care | Industry: Biotechnology

ADMA Biologics (ADMA)

Market Price (12/29/2025): $19.1
Market Cap: $4.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 34%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 70x
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%	Key risks ADMA key risks include [1] its history of substantial operating losses and a $506.3 million accumulated deficit, Show more.
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Plasma-Derived Therapies, Targeted Therapies, Show more.

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 34%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Plasma-Derived Therapies, Targeted Therapies, Show more.
3	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 70x
4	Key risks ADMA key risks include [1] its history of substantial operating losses and a $506.3 million accumulated deficit, Show more.

Valuation, Metrics & Events

	12/29/25	2024	2023	2022	2021
Share Price CYE	$19.10	$17.15	$4.52	$3.88	$1.41
Market Cap CYE ($ Bil)	4.6	4.1	1.0	0.8	0.3
Total Debt ($ Bil)	0.1	0.1	0.1	0.2	0.1
Total Cash ($ Bil)	0.1	0.1	0.1	0.1	0.1
Enterprise Value ($ Bil)	4.6	4.2	1.1	1.0	0.4
Valuation Ratios
P/S TTM	9.3	9.4	3.9	5.0	2.4
P/EBIT TTM	27.8	28.6	-315.2	-16.5	-3.4
P/E TTM	21.8	20.2	-35.9	-11.6	-2.7
P/FCF TTM	112.2	36.3	265.1	-10.5	-1.6
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/29/25	2024	2023
Share Price CYE	$19.10	$17.15	$4.52
Market Cap CYE ($ Bil)	4.6	4.1	1.0
Total Debt ($ Bil)	0.1	0.1	0.1
Total Cash ($ Bil)	0.1	0.1	0.1
Enterprise Value ($ Bil)	4.6	4.2	1.1
Valuation Ratios
P/S TTM	9.3	9.4	3.9
P/EBIT TTM	27.8	28.6	-315.2
P/E TTM	21.8	20.2	-35.9
P/FCF TTM	112.2	36.3	265.1
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	ADMA	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.5
Rev Chg Q	12.0%	7.3%
Rev Chg LTM	27.6%	6.1%
Rev Chg 3Y Avg	56.9%	5.5%
PROFITABILITY	VERY GOOD
Op Inc LTM ($ Bil)	0.2
CFO LTM ($ Bil)	0.1
Net Inc LTM ($ Bil)	0.2
Op Mgn LTM	34.2%	18.8%
CFO/Rev LTM	13.3%	20.4%
Net Inc Mgn	42.9%	13.1%
VALUATION	HIGH
P/S	9.3	3.3
P/CFO	70.1	15.8
P/FCF	112.2	20.7
P/E	21.8	23.7
STABILITY	VERY GOOD
Debt/Equity	0.02	0.21
Cash/Assets	0.11	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of FDA-Approved Plasma Collection Centers	9	7192023	Link
Number of FDA-Approved Products	3	4262021	Link
Annual Plasma Fractionation and Purification Capacity	up to ~600,000 Liters	5132024	Link
Number of Issued U.S. Patents	5	11152017	Link
Pipeline Programs in Development	SG-001	11052025	Link

Upcoming
3/02/2026	Earnings Release	Rev: - EPS: -

ADMA Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

1. Third Quarter 2025 Financial Performance and Raised Guidance. ADMA Biologics reported strong third-quarter 2025 financial results on November 5, 2025, with total revenue reaching $134.2 million, a 12% year-over-year increase that exceeded consensus estimates. The company also significantly improved its gross margin to 56.3% from 49.8% in the prior year and increased its adjusted EBITDA by 29% to $58.7 million. Following these results, ADMA raised its full-year 2025 revenue guidance to at least $510 million and its 2026 revenue guidance to at least $630 million, signaling continued strong growth. The stock saw a 4.78% increase in regular trading hours following the earnings release.

2. FDA Lot Release of Yield-Enhanced Production Batches. Concurrent with its third-quarter earnings on November 5, 2025, ADMA Biologics announced the FDA lot release of its first yield-enhanced commercial production batches. This milestone is expected to significantly increase finished immunoglobulin output by approximately 20% from the same plasma input, which is projected to drive sustained gross margin expansion starting in the fourth quarter of 2025 and continuing into 2026 and beyond.

Show more

Stock Movement Drivers

Fundamental Drivers

The 29.9% change in ADMA stock from 9/29/2025 to 12/29/2025 was primarily driven by a 28.1% change in the company's P/E Multiple.

	9292025	12292025	Change
Stock Price ($)	14.70	19.10	29.93%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	474.17	488.56	3.03%
Net Income Margin (%)	44.06%	42.87%	-2.70%
P/E Multiple	16.99	21.76	28.06%
Shares Outstanding (Mil)	241.49	238.60	1.20%
Cumulative Contribution			29.91%

LTM = Last Twelve Months as of date shown

Market Drivers

9/29/2025 to 12/29/2025

	Return	Correlation
ADMA	30.0%
Market (SPY)	3.6%	46.7%
Sector (XLV)	14.7%	42.5%

Fundamental Drivers

The 4.9% change in ADMA stock from 6/30/2025 to 12/29/2025 was primarily driven by a 6.4% change in the company's Total Revenues ($ Mil).

	6302025	12292025	Change
Stock Price ($)	18.21	19.10	4.89%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	459.38	488.56	6.35%
Net Income Margin (%)	45.01%	42.87%	-4.76%
P/E Multiple	20.94	21.76	3.91%
Shares Outstanding (Mil)	237.78	238.60	-0.35%
Cumulative Contribution			4.89%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2025 to 12/29/2025

	Return	Correlation
ADMA	4.9%
Market (SPY)	11.6%	37.0%
Sector (XLV)	16.1%	40.5%

Fundamental Drivers

The 9.5% change in ADMA stock from 12/29/2024 to 12/29/2025 was primarily driven by a 140.9% change in the company's Net Income Margin (%).

	12292024	12292025	Change
Stock Price ($)	17.45	19.10	9.46%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	382.81	488.56	27.62%
Net Income Margin (%)	17.80%	42.87%	140.87%
P/E Multiple	60.08	21.76	-63.78%
Shares Outstanding (Mil)	234.57	238.60	-1.72%
Cumulative Contribution			9.42%

LTM = Last Twelve Months as of date shown

Market Drivers

12/29/2024 to 12/29/2025

	Return	Correlation
ADMA	9.5%
Market (SPY)	16.6%	42.6%
Sector (XLV)	13.6%	40.8%

Fundamental Drivers

The 392.3% change in ADMA stock from 12/30/2022 to 12/29/2025 was primarily driven by a 274.4% change in the company's Total Revenues ($ Mil).

	12302022	12292025	Change
Stock Price ($)	3.88	19.10	392.27%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	130.48	488.56	274.43%
P/S Multiple	5.84	9.33	59.74%
Shares Outstanding (Mil)	196.38	238.60	-21.50%
Cumulative Contribution			369.52%

LTM = Last Twelve Months as of date shown

Market Drivers

12/30/2023 to 12/29/2025

	Return	Correlation
ADMA	322.8%
Market (SPY)	47.9%	36.1%
Sector (XLV)	17.6%	34.5%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ADMA Return	-51%	-28%	175%	16%	279%	12%	382%
Peers Return	16%	38%	-12%	21%	26%	16%	151%
S&P 500 Return	16%	27%	-19%	24%	23%	17%	114%
Monthly Win Rates [3]
ADMA Win Rate	33%	50%	83%	42%	75%	58%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
ADMA Max Drawdown	-62%	-44%	-9%	-22%	-3%	-18%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See ADMA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/29/2025 (YTD)

How Low Can It Go

Unique Key	Event	ADMA	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-63.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	170.6%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	395 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-67.3%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	206.0%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	1,244 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-68.3%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	215.7%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	1,958 days	120 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

ADMA Biologics's stock fell -63.1% during the 2022 Inflation Shock from a high on 2/9/2021. A -63.1% loss requires a 170.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About ADMA Biologics (ADMA)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe ADMA Biologics:

A smaller, specialized Grifols, focusing on plasma-derived therapies like IVIG.
An integrated biopharmaceutical company that develops and manufactures plasma-derived medicines, similar to a specialized division of CSL Behring.

AI Analysis | Feedback

BIVIGAM®: An immune globulin intravenous (human) used to treat primary humoral immunodeficiency (PI) in adults and pediatric patients.
ASCENIV™: An immune globulin intravenous (human, liquid) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients aged 12 years and older.
NABI-HB®: A hepatitis B immune globulin (human) used for immediate and long-term protection against hepatitis B virus infection.

AI Analysis | Feedback

ADMA Biologics (ADMA) sells primarily to other companies, not directly to individuals.

ADMA's sales and distribution strategy involves marketing its specialized plasma-derived biologics (such as BIVIGAM, ASCENIV, and NABI-HB) through a direct sales force in the United States. Its direct customers, which facilitate the distribution and administration of its products to end-users, include:

Wholesale drug distributors
Specialty pharmacies
Hospitals
Alternate treatment sites (e.g., infusion centers)
Physician offices
Group Purchasing Organizations (GPOs)

Regarding its major customers, ADMA's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, states that the company depends on a limited number of specialty distributors and wholesale customers. The report indicates that two customers individually represented more than 10% of ADMA's total net product sales, accounting for approximately 42% and 15% of net product sales, respectively, for that year. However, ADMA Biologics does not explicitly name these specific customer companies in its public filings.

AI Analysis | Feedback

BPL Plasma Inc.

AI Analysis | Feedback

Adam S. Grossman, Founder, Director, President, & Chief Executive Officer
Mr. Grossman founded ADMA Biologics in 2007 and has served as President and Chief Executive Officer since October 2011. He was previously Executive Vice President of National Hospital Specialties and GenesisBPS from 1994 to 2011. GenesisBPS, a medical device firm, was acquired in September 2025. Mr. Grossman led ADMA's public offering in 2013 and has completed over $1.2 billion in equity capital markets financing and debt transactions. He also led the asset acquisition of the Biotest Therapy Business Unit in 2017. His career also includes roles at MedImmune, Inc. and the American Red Cross. He is the son of co-founder Dr. Jerrold B. Grossman.

Brad L. Tade, Chief Financial Officer & Treasurer
Mr. Tade joined ADMA Biologics in June 2023 as Vice President of Financial Operations and was appointed Chief Financial Officer & Treasurer. He brings over 20 years of experience in the medical device industry. Prior to ADMA, he served as Vice President of Finance for Commercial Packaging Technology and Development and Manufacturing at PCI Pharma Services, and previously held Vice President of Finance roles at Baxter and Becton Dickinson.

Kaitlin Kestenberg, Chief Operating Officer & Senior Vice President, Compliance
Ms. Kestenberg has been the Chief Operating Officer and Senior Vice President, Compliance of ADMA Biologics since April 2024. Her background includes quality and operational leadership positions at Merck, Charles River Laboratories, BioReliance, and ElevateBio.

Jerrold B. Grossman, D.P.S., Founder & Vice Chairman
Dr. Grossman is a co-founder of ADMA Biologics in 2007 and has over 35 years of experience in the blood and plasma industry. He is the founder and CEO of Technomed, Inc. (formerly National Hospital Specialties) since 1980, and was the founder and President of GenesisBPS from 1990 until its acquisition in September 2025. Dr. Grossman was also a founder and former director of Pascack Bancorp, Inc., which was acquired by Lakeland Bancorp, Inc. in January 2016.

Steven A. Elms, Chairman
Mr. Elms has served as a director of ADMA Biologics since 2007 and is the company's Chairman of the Board. He is a Managing Partner at Aisling Capital, a life sciences-focused private equity firm, which he joined in 2000. Previously, he was a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist, where he was involved in over 60 financing and merger and acquisition transactions. Mr. Elms also serves on the board of directors for other companies, including Elevation Oncology and Marker Therapeutics.

AI Analysis | Feedback

ADMA Biologics (ADMA) faces several key risks to its business operations, primarily centered around its financial stability, regulatory compliance, and production capabilities. The most significant risk category for ADMA Biologics is **Finance & Corporate**, accounting for 32% of identified risks. The company has a history of operating losses, incurring net losses of $71.6 million in 2021, $65.9 million in 2022, and $28.2 million in 2023, resulting in an accumulated deficit of $506.3 million through December 31, 2023. While ADMA Biologics generated positive cash flow from operations in 2023, it had consumed substantial amounts of cash since its inception, with negative cash flows from operations in 2021 and 2022. There is also a risk that the company may not achieve profitability in 2024 and beyond. Furthermore, the liquidity of ADMA's securities could be impaired, and there's a risk of delisting from the Nasdaq Global Market if it fails to adhere to strict listing requirements. A substantial risk also stems from **Legal & Regulatory** factors, representing 26% of the company's risk profile. As a biopharmaceutical company, ADMA Biologics is subject to rigorous regulatory oversight, and changes in regulations or difficulties in maintaining compliance could impact its stock value and operations. **Production Risks** constitute 21% of the identified risks. The manufacturing process for biologics, such as immune globulin (IG), is inherently complex and time-consuming, typically taking 7 to 12 months from collection to release. This complexity means that challenges related to manufacturing efficiency, quality control (cGMP), and potential supply chain disruptions, including those influenced by geopolitical conditions, could materially affect the business.

AI Analysis | Feedback

The emergence of curative gene therapies for specific types of primary immunodeficiency (PI) represents a clear emerging threat. ADMA Biologics' core products, BIVIGAM and ASCENIV, are plasma-derived intravenous immune globulins (IVIG) used for the chronic treatment of PI. Gene therapies, currently in various stages of clinical development and gaining increasing regulatory attention and approvals for certain rare genetic diseases, aim to provide a one-time, potentially curative solution by correcting the underlying genetic defect responsible for the immunodeficiency. Should these gene therapies prove safe, effective, and broadly applicable to a wider range of PI patients, they could significantly reduce or eliminate the long-term need for chronic immunoglobulin replacement therapy, thereby diminishing the market for ADMA's primary product offerings.

AI Analysis | Feedback

ADMA Biologics (ADMA) primarily focuses on specialty plasma-derived biologics, with its main commercial products being intravenous immune globulin (IVIG) therapies, ASCENIV and BIVIGAM, and a hyperimmune globulin product, Nabi-HB. The company is also developing SG-001, a pre-clinical hyperimmune globulin.

Addressable Markets for ADMA Biologics' Main Products:

Intravenous Immune Globulin (IVIG) Market:

The U.S. intravenous immunoglobulin market was valued at approximately USD 7.27 billion in 2024 and is projected to reach USD 14.42 billion by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 7.9% from 2024 to 2033. Another estimate places the U.S. IVIG market at USD 4.94 billion in 2025, growing to USD 9.28 billion by 2034, at a CAGR of 7.25%.
Globally, the intravenous immunoglobulin market was valued at approximately USD 14.32 billion in 2024 and is projected to grow to USD 28.70 billion by 2034, at a CAGR of 7.20% from 2025 to 2034. Another report estimates the global market at USD 17.34 billion in 2025, expected to reach USD 34.92 billion by 2034, with an 8.10% CAGR from 2025 to 2034.

Hyperimmune Globulins Market:

The global hyperimmune globulins market size was approximately USD 1.94 billion in 2024 and is projected to reach USD 3.56 billion by 2033, growing at a CAGR of 7% from 2025 to 2033. Other estimations value the global market at USD 1.7 billion in 2023, expected to reach USD 3.2 billion by 2033 at a CAGR of 6.2% from 2024 to 2033.
The U.S. hyperimmune globulins market accounts for approximately 33% of the global demand. Hepatitis B Immunoglobulins, like ADMA's Nabi-HB, represent about 24% of the hyperimmune globulins market.

AI Analysis | Feedback

ADMA Biologics (ADMA) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

Growing Demand and Utilization of ASCENIV: The company anticipates continued revenue growth due to strong performance, increased prescriber adoption, and growing patient demand for its lead product, ASCENIV. This product achieved record utilization in recent quarters.
Yield-Enhancement Production Efficiencies: The FDA's approval of a new production process and yield-enhancement technology is projected to increase finished immunoglobulin (IG) output by 20% or more, using the same amount of starting plasma. This efficiency gain is expected to drive margin expansion and support revenue growth through 2026.
Expansion of Payer Coverage and Distribution Partnerships: Positive negotiations for 2026 payer coverage and ongoing efforts to onboard additional distribution partners are expected to broaden the reach and improve access for both Bivigam and ASCENIV, thereby accelerating growth.
New High-Titer Plasma Supply Contracts and Expanded Sourcing: ADMA has secured new high-titer plasma supply contracts and expanded its plasma sourcing. This strengthens the market potential of products like ASCENIV, de-risks the supply chain, and supports long-term revenue growth.
Potential Launch of Pipeline Product SG-001: Although currently excluded from official revenue guidance, the pipeline product SG-001 represents a significant upside opportunity. If approved, it has the potential to generate substantial high-margin annual revenue, estimated between $300 million and $500 million or more.

AI Analysis | Feedback

Share Repurchases

ADMA Biologics announced a $500 million share repurchase program in the first quarter of 2025.
Under this program, approximately $15 million of common stock was repurchased during the second quarter of 2025, with settlements occurring in July 2025.
The share repurchase program does not have an expiration date.

Share Issuance

The number of ADMA Biologics' outstanding shares increased by 3.49% in one year.

Capital Expenditures

ADMA Biologics' latest trailing twelve months (TTM) Capital Expenditure % Average for three years is 14.07%.
Over the past five years, the company's average Capital Expenditure % Average for three years has been 14.53%.
A decrease in cash and cash equivalents from $103.1 million at the end of 2024 to $61.4 million as of September 30, 2025, indicates significant investments or expenditures during this period.

Better Bets than ADMA Biologics (ADMA)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADMA: 56.9% | 9.3x)

TGTX (1272.3% | 8.3x)

TG Therapeutics

MIRM (114.2% | 8.6x)

Mirum Pharmaceuticals

TVTX (70.5% | 8.0x)

Travere Therapeutics

APLS (115.2% | 3.1x)

Apellis Pharmaceuticals

STOK (403.5% | 9.2x)

Stoke Therapeutics

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADMA: 56.9% | 27.3x)

MNKD (66.8% | 23.2x)

MannKind

CRMD (14254.7% | 9.3x)

Cormedix

KROS (15245.3% | 18.7x)

Keros Therapeutics

ATRA (689.7% | 9.1x)

Atara Biotherapeutics

Higher Rev Chg LTM (Value for ADMA: 27.6%)

MDGL (864.2%)

Madrigal Pharmaceuticals

RNA (106.3%)

Avidity Biosciences

BBIO (62.5%)

BridgeBio Pharma

ALNY (53.2%)

Alnylam Pharmaceuticals

INSM (30.3%)

Insmed

Higher Rev Chg 3Y Avg (Value for ADMA: 56.9%)

ARWR (7719.5%)

Arrowhead Pharmaceuticals

CYTK (818.6%)

Cytokinetics

BBIO (727.6%)

BridgeBio Pharma

AXSM (296.0%)

Axsome Therapeutics

RYTM (136.1%)

Rhythm Pharmaceuticals

Higher Op Mgn LTM (Value for ADMA: 34.2%)

RPRX (65.2%)

Royalty Pharma

HALO (59.3%)

Halozyme Therapeutics

UTHR (48.7%)

United Therapeutics

GILD (38.3%)

Gilead Sciences

EXEL (35.8%)

Exelixis

Higher CFO/Rev LTM (Value for ADMA: 13.3%)

AMGN (36.5%)

Amgen

REGN (35.6%)

Regeneron Pharmaceuticals

ABBV (35.0%)

AbbVie

GILD (33.2%)

Gilead Sciences

VRTX (31.7%)

Vertex Pharmaceuticals

Higher FCF/Rev LTM (Value for ADMA: 8.3%)

ABBV (33.0%)

AbbVie

AMGN (32.1%)

Amgen

GILD (31.5%)

Gilead Sciences

VRTX (28.5%)

Vertex Pharmaceuticals

REGN (27.2%)

Regeneron Pharmaceuticals

Higher Total Yield (Value for ADMA: 4.6%)

GILD (7.8%)

Gilead Sciences

AMGN (6.8%)

Amgen

BIIB (6.2%)

Biogen

REGN (6.0%)

Regeneron Pharmaceuticals

UTHR (5.8%)

United Therapeutics

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADMA: 56.9% | 9.3x)

HIMS (71.0% | 3.5x)

Hims & Hers Health

TGTX (1272.3% | 8.3x)

TG Therapeutics

TMDX (105.9% | 7.4x)

TransMedics

MIRM (114.2% | 8.6x)

Mirum Pharmaceuticals

TVTX (70.5% | 8.0x)

Travere Therapeutics

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADMA: 56.9% | 27.3x)

MNKD (66.8% | 23.2x)

MannKind

NUTX (87.7% | 3.4x)

Nutex Health

CRMD (14254.7% | 9.3x)

Cormedix

KROS (15245.3% | 18.7x)

Keros Therapeutics

SIGA (104.9% | 5.0x)

SIGA Technologies

Higher Rev Chg LTM (Value for ADMA: 27.6%)

BBIO (62.5%)

BridgeBio Pharma

ALNY (53.2%)

Alnylam Pharmaceuticals

NTRA (38.2%)

Natera

LLY (36.8%)

Eli Lilly

INSM (30.3%)

Insmed

Higher Rev Chg 3Y Avg (Value for ADMA: 56.9%)

ARWR (7719.5%)

Arrowhead Pharmaceuticals

BBIO (727.6%)

BridgeBio Pharma

AXSM (296.0%)

Axsome Therapeutics

HIMS (71.0%)

Hims & Hers Health

TEM (59.8%)

Tempus AI

Higher Op Mgn LTM (Value for ADMA: 34.2%)

UTHR (48.7%)

United Therapeutics

LLY (43.0%)

Eli Lilly

GILD (38.3%)

Gilead Sciences

ZTS (37.6%)

Zoetis

MRK (34.9%)

Merck

Higher CFO/Rev LTM (Value for ADMA: 13.3%)

ABBV (35.0%)

AbbVie

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

LLY (20.5%)

Eli Lilly

TMO (17.5%)

Thermo Fisher Scientific

Higher FCF/Rev LTM (Value for ADMA: 8.3%)

ABBV (33.0%)

AbbVie

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

ABT (15.8%)

Abbott Laboratories

TMO (14.0%)

Thermo Fisher Scientific

Higher Total Yield (Value for ADMA: 4.6%)

MRK (10.2%)

Merck

UNH (8.5%)

UnitedHealth

ABT (8.3%)

Abbott Laboratories

JNJ (7.5%)

Johnson & Johnson

AMGN (6.8%)

Amgen

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADMA: 56.9% | 9.3x)

APO (89.3% | 3.2x)

Apollo Asset Management

NU (62.1% | 8.4x)

SLF (88.9% | 1.0x)

Sun Life Financial

RIVN (103.0% | 4.3x)

Rivian Automotive

CRCL (514.0% | 7.7x)

Circle Internet

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADMA: 56.9% | 27.3x)

APO (89.3% | 10.7x)

Apollo Asset Management

SMCI (63.1% | 19.3x)

Super Micro Computer

FTAI (66.9% | 24.3x)

FTAI Aviation

HUT (135.5% | 12.8x)

Hut 8

ORLA (81.9% | 14.9x)

Orla Mining

Higher Rev Chg LTM (Value for ADMA: 27.6%)

APP (86.4%)

AppLovin

NVDA (65.2%)

NVIDIA

PLTR (47.2%)

Palantir Technologies

MU (45.4%)

Micron Technology

AMD (31.8%)

Advanced Micro Devices

Higher Rev Chg 3Y Avg (Value for ADMA: 56.9%)

NVDA (91.6%)

NVIDIA

CRDO (90.5%)

Credo Technology

APO (89.3%)

Apollo Asset Management

SLF (88.9%)

Sun Life Financial

NU (62.1%)

Higher Op Mgn LTM (Value for ADMA: 34.2%)

NVDA (58.8%)

NVIDIA

MA (58.3%)

Mastercard

MSFT (46.3%)

Microsoft

META (43.2%)

Meta Platforms

AVGO (40.8%)

Broadcom

Higher CFO/Rev LTM (Value for ADMA: 13.3%)

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

AMZN (18.1%)

Amazon.com

Higher FCF/Rev LTM (Value for ADMA: 8.3%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

META (23.7%)

Meta Platforms

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

Higher Total Yield (Value for ADMA: 4.6%)

XOM (9.1%)

Exxon Mobil

BAC (7.2%)

Bank of America

JPM (6.5%)

JPMorgan Chase

BRK-B (6.2%)

Berkshire Hathaway

V (5.1%)

Visa

		Best Bets In Health Care Sector
	ADMA	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	21.8	22.1	13.6	32.8	13.6	11.8	78.6	74.7	28.0	11.4	57.7
P/EBIT	27.8	10.7	10.6	33.6	11.4	8.9	57.2	72.9	27.4	7.7	67.1
What You Get
Rev Chg Q	12.0%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	27.6%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	56.9%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	6.3%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	ADMA Biologics Earnings Notes
2	ADMA Biologics Earnings Notes
3	Is ADMA Biologics Stock Trading At A Bargain?	Actionable
4	With ADMA Biologics Stock Surging, Have You Considered The Downside?	Return
5	ADMA Biologics vs Krystal Biotech: Which Is A Better Investment?	Counter-Intuitive Comparisons
6	ADMA Biologics (ADMA) Net Income Comparison	Financials
7	ADMA Biologics (ADMA) Revenue Comparison	Financials
8	ADMA Biologics (ADMA) Operating Cash Flow Comparison	Financials
9	ADMA Biologics (ADMA) Tax Expense Comparison	Financials
10	ADMA Biologics (ADMA) Debt Comparison	Financials

	Title
0	ARTICLES

Trade Ideas

Select ideas related to ADMA. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%
ADMA_9052025_Dip_Buyer_ValueBuy	09052025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	14.3%	14.3%	-17.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PRAX	Praxis Precision Medicines	6.7	13.2%	295.8%
HPK	HighPeak Energy	0.6	9.8%	-67.5%
DBRG	DigitalBridge	2.7	9.6%	35.7%
METCB	Ramaco Resources	0.7	8.8%	49.5%
AQST	Aquestive Therapeutics	0.7	8.0%	81.7%
PGEN	Precigen	1.3	7.0%	297.3%
BW	Babcock & Wilcox Enterprises	0.5	5.5%	237.8%
OMER	Omeros	1.0	5.5%	67.7%
SCHL	Scholastic	0.8	4.8%	49.7%
EVMN	Evommune	0.5	4.6%	-11.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
RARE	Ultragenyx Pharmaceutical	2.0	-42.3%	-53.1%
USAS	Americas Gold And Silver	1.4	-12.5%	475.7%
UAMY	United States Antimony	0.7	-10.1%	216.9%
UP	Wheels Up Experience	0.4	-9.8%	-63.3%
ITRG	Integra Resources	0.7	-9.6%	366.7%
BRBR	BellRing Brands	3.5	-9.4%	-63.7%
RZLT	Rezolute	0.3	-9.0%	-50.4%
SGML	Sigma Lithium	1.5	-8.8%	17.9%
IMSR	Terrestrial Energy	0.6	-8.5%	-59.4%
ZBIO	Zenas BioPharma	1.6	-8.1%	376.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	1.0	72.6%	67.7%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
RZLT	Rezolute	0.3	37.3%	-50.4%
ADEA	Adeia	1.9	35.6%	25.7%
METC	Ramaco Resources	1.1	25.1%	80.3%
AAOI	Applied Optoelectronics	2.3	17.3%	-0.3%
BNTC	Benitec Biopharma	0.6	17.3%	6.8%
UAMY	United States Antimony	0.7	16.4%	216.9%
DBRG	DigitalBridge	2.7	15.7%	35.7%
METCB	Ramaco Resources	0.7	15.5%	49.5%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.8	-67.2%	-19.6%
RARE	Ultragenyx Pharmaceutical	2.0	-41.1%	-53.1%
LAB	Standard BioTools	0.5	-21.5%	-26.9%
NNE	Nano Nuclear Energy	1.0	-20.0%	6.1%
TMC	TMC The Metals	2.3	-19.9%	464.3%
IMSR	Terrestrial Energy	0.6	-18.9%	-59.4%
DJT	Trump Media & Technology	3.7	-18.2%	-61.4%
TLRY	Tilray Brands	9.8	-17.0%	-30.4%
EVEX	Eve	1.3	-16.5%	-26.3%
TDUP	ThredUp	0.8	-16.2%	351.1%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	9.8	799.0%	-30.4%
HPP	Hudson Pacific Properties	4.7	428.6%	-51.2%
WVE	WAVE Life Sciences	2.9	132.9%	44.4%
OMER	Omeros	1.0	72.1%	67.7%
PL	Planet Labs PBC	6.0	69.5%	391.8%
LUNR	Intuitive Machines	1.8	69.0%	-13.5%
RKLB	Rocket Lab	36.1	67.2%	175.3%
TE	T1 Energy	1.0	67.2%	372.1%
PRAX	Praxis Precision Medicines	6.7	61.5%	295.8%
DBRG	DigitalBridge	2.7	60.3%	35.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-74.6%	-50.4%
JANX	Janux Therapeutics	0.9	-59.4%	-73.7%
FRMI	Fermi	5.3	-52.4%	-76.9%
LENZ	LENZ Therapeutics	0.5	-46.2%	-42.8%
RARE	Ultragenyx Pharmaceutical	2.0	-41.6%	-53.1%
NKTR	Nektar Therapeutics	0.6	-35.0%	206.3%
GOGO	Gogo	0.6	-33.9%	-42.2%
SYM	Symbotic	6.5	-31.5%	152.3%
IMSR	Terrestrial Energy	0.6	-30.9%	-59.4%
ORIC	ORIC Pharmaceuticals	0.6	-30.2%	2.2%

Peer Comparisons for ADMA Biologics

Peers to compare with:

Financials

	ADMA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ADMA Bio.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	19.10	22.72	24.36	305.78	78.05	273.60	51.20
Mkt Cap	4.6	21.4	32.5	285.6	308.8	4,077.4	159.0
Rev LTM	489	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	167	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	41	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	32	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	65	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	45	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	ADMA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ADMA Bio.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	27.6%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	56.9%	-3.9%	6.5%	2.6%	3.7%	1.8%	3.2%
Rev Chg Q	12.0%	4.2%	14.4%	9.1%	7.5%	9.6%	9.4%
QoQ Delta Rev Chg LTM	3.0%	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	34.2%	6.6%	4.8%	17.7%	22.5%	31.9%	20.1%
Op Mgn 3Y Avg	21.6%	7.4%	7.2%	16.4%	24.2%	30.8%	19.0%
QoQ Delta Op Mgn LTM	1.4%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	13.3%	6.7%	8.5%	20.6%	23.8%	26.6%	17.0%
CFO/Rev 3Y Avg	9.6%	6.8%	12.7%	21.4%	26.1%	28.4%	17.1%
FCF/Rev LTM	8.3%	5.1%	1.8%	18.1%	22.1%	23.5%	13.2%
FCF/Rev 3Y Avg	6.3%	5.5%	4.6%	18.6%	24.6%	25.6%	12.5%

Valuation

	ADMA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ADMA Bio.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	4.6	21.4	32.5	285.6	308.8	4,077.4	159.0
P/S	9.3	0.4	0.9	4.4	5.4	10.0	4.9
P/EBIT	27.8	6.6	19.8	25.1	22.5	31.3	23.8
P/E	21.8	8.4	569.7	36.1	29.9	41.1	33.0
P/CFO	70.1	5.8	11.1	21.2	22.5	37.6	21.8
Total Yield	4.6%	14.4%	2.3%	5.0%	5.5%	2.8%	4.8%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-0.0%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.0	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	0.0	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	ADMA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ADMA Bio.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	-0.4%	-5.9%	12.1%	-0.9%	1.4%	-1.9%	-0.7%
3M Rtn	29.9%	-14.5%	1.5%	9.9%	15.9%	7.6%	8.8%
6M Rtn	4.9%	-5.1%	20.5%	5.0%	13.9%	33.6%	9.4%
12M Rtn	9.5%	-28.7%	15.5%	40.8%	34.3%	7.5%	12.5%
3Y Rtn	392.3%	-5.4%	66.0%	142.1%	78.8%	113.8%	96.3%
1M Excs Rtn	-1.6%	-5.5%	12.5%	-0.5%	1.2%	-2.8%	-1.0%
3M Excs Rtn	26.3%	-18.2%	-2.2%	6.2%	12.3%	4.0%	5.1%
6M Excs Rtn	-6.4%	-16.4%	9.2%	-6.3%	2.5%	22.3%	-1.9%
12M Excs Rtn	-4.6%	-43.4%	-0.1%	25.4%	19.4%	-7.9%	-2.3%
3Y Excs Rtn	339.6%	-82.8%	-10.2%	62.0%	0.5%	27.0%	13.7%

Comparison Analyses

	Title
0	Adma Biologics Inc Com vs Liberty Media: Similar Income; Which Stock Is A Better Bet?
1	Adma Biologics Inc Com vs Culp: Similar Market Cap; Which Stock Is A Better Bet?
2	Adma Biologics Inc Com vs Bassett Furniture Industries: Similar Market Cap; Which Stock Is A Better Bet?
3	Adma Biologics Inc Com vs iBio: Similar Market Cap; Which Stock Is A Better Bet?

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/5/2025	3/18/2025	2/28/2024	3/23/2023	3/24/2022	3/25/2021	3/13/2020
Key Financials
Total Revenue	489	426	258	154	81	42	29
EBITDA	172	148	5	-40	-53	-60	-36
Operating Income	167	139	22	-39	-58	-65	-41
Net Income	209	198	-28	-66	-72	-76	-48
EPS	0.87	0.85	-0.13	-0.33	-0.51	-0.88	-0.89
Growth Rates
Total Revenue Growth	27.6%	65.2%	67.6%	90.4%	91.7%	43.9%	72.8%
EBITDA Growth	74.2%	2784.6%	113.0%	25.6%	11.2%	-66.0%	36.5%
Operating Income Growth	45.4%	542.5%	155.0%	32.6%	10.1%	-56.7%	31.3%
Net Income Growth	207.4%	800.0%	57.2%	8.0%	5.4%	-56.9%	26.6%
Margins
EBITDA Margin	35.2%	34.6%	2.0%	-25.6%	-65.6%	-141.7%	-122.8%
Operating Income Margin	34.2%	32.6%	8.4%	-25.5%	-72.1%	-153.8%	-141.1%
Net Income Margin	42.9%	46.4%	-10.9%	-42.8%	-88.5%	-179.4%	-164.5%
Cash & Debt
Total Cash	61	103	51	87	51	56	27
Total Debt	83	82	141	154	103	98	85
Net Debt / (Cash)	22	-21	90	68	52	42	58
Cash Flows
Net Cash from Operations	65	119	9	-60	-112	-102	-76
Free Cash from Operations	41	110	4	-73	-126	-115	-80
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/5/2025	8/6/2025	5/7/2025	3/18/2025	11/7/2024	8/8/2024	5/9/2024	2/28/2024	11/8/2023	8/9/2023	5/10/2023	3/23/2023
Key Financials Quarterly
Total Revenue	134	122	115	118	120	107	82	74	67	60	57	50
Ebitda	51	44	37	40	42	42	24	-9	11	2	1	-5
Operating Income	51	43	35	38	40	39	22	14	9	-0	-1	-6
Net Income	36	34	27	112	36	32	18	-18	3	-6	-7	-12
EPS	0.15	0.14	0.11	0.47	0.15	0.14	0.08	-0.08	0.01	-0.03	-0.03	-0.06
Key Financials TTM
Total Revenue TTM	489	474	459	426	383	330	283	258	234	208	182	154
Ebitda TTM	172	163	161	148	99	68	28	5	10	-9	-18	-40
Operating Income TTM	167	156	152	139	115	84	44	22	1	-17	-25	-39
Net Income TTM	209	209	207	198	68	35	-4	-28	-23	-40	-48	-66
Growth Rates Quarterly
Total Revenue Growth	12.0%	13.8%	40.2%	59.1%	78.1%	78.3%	43.9%	47.9%	63.7%	77.3%	95.6%	89.4%
EBITDA Growth	21.4%	5.5%	54.0%	524.2%	281.6%	1957.3%	1686.9%	-104.5%	248.2%	127.1%	106.8%	61.4%
Operating Income Growth	28.7%	9.2%	59.9%	169.3%	356.4%	8387.7%	2784.0%	334.9%	193.2%	94.8%	94.5%	54.1%
Net Income Growth	1.4%	6.7%	51.1%	734.2%	1300.0%	603.2%	362.3%	-44.3%	117.2%	53.7%	72.9%	26.5%
Margins Quarterly
EBITDA Margin	38.2%	36.1%	32.6%	33.6%	35.2%	38.9%	29.7%	-12.6%	16.4%	3.4%	2.4%	-9.1%
Operating Income Margin	38.0%	35.1%	30.4%	32.6%	33.1%	36.6%	26.7%	19.3%	12.9%	-0.8%	-1.4%	-12.1%
Net Income Margin	27.1%	28.1%	23.4%	95.2%	30.0%	29.9%	21.7%	-23.9%	3.8%	-10.6%	-11.9%	-24.5%
Cash & Debt
Total Cash	61	90	72	103	87	88	45	51	74	63	69	87
Total Debt	83	84	82	82	111	141	141	141	153	152	156	154
Net Debt / (Cash)	22	-6	10	-21	25	53	96	90	79	89	87	68
Cash Flows Quarterly
FCF from Operations	13	21	-20	50	25	46	-2	18	12	-6	-15	-7
Cash Flows TTM
FCF from Operations TTM	65	77	101	119	86	73	21	9	-16	-41	-48	-60
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	24.4%	23.4%	16.9%	24.1%	22.9%	20.1%	11.4%	7.8%	4.8%	-0.3%	-0.5%	-3.5%
Return on Invested Capital (ROIC) TTM
ROIC TTM	26.1%	24.9%	22.8%	21.8%	15.8%	10.7%	6.0%	3.0%	0.2%	-2.3%	-3.5%	-5.6%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
ADMA BioManufacturing	250	144	75	37	22
Plasma Collection Centers	8	10	6	5	7
License revenue	0
Corporate		0	0	0	0
Total	258	154	81	42	29

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
ADMA BioManufacturing	247	238	208	141	100
Corporate	48	73	43	54	23
Plasma Collection Centers	35	37	25	13	4
Total	329	348	276	208	127

Price Behavior

Price Behavior

Market Price	$19.11
Market Cap ($ Bil)	4.6
First Trading Date	10/17/2013
Distance from 52W High	-22.0%
	50 Days	200 Days
DMA Price	$17.33	$18.20
DMA Trend	up	up
Distance from DMA	10.2%	5.0%
	3M	1YR
Volatility	46.2%	51.9%
Downside Capture	149.06	135.78
Upside Capture	252.20	124.31
Correlation (SPY)	44.0%	42.6%

ADMA Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	2.67	1.70	1.50	1.57	1.13	1.23
Up Beta	0.70	1.27	2.25	1.87	0.99	0.96
Down Beta	1.18	1.47	1.44	0.77	1.01	1.34
Up Capture	632%	325%	148%	152%	139%	481%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	12	24	30	60	123	377
Down Capture	214%	120%	121%	197%	123%	103%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	7	17	31	63	122	354

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of ADMA With Other Asset Classes (Last 1Y)
	ADMA	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	7.8%	13.8%	16.7%	65.4%	7.5%	4.2%	-7.3%
Annualized Volatility	51.6%	17.2%	19.4%	19.8%	15.3%	17.0%	34.9%
Sharpe Ratio	0.32	0.59	0.67	2.43	0.27	0.08	-0.05
Correlation With Other Assets		40.6%	42.3%	10.2%	8.2%	31.0%	21.9%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of ADMA With Other Asset Classes (Last 5Y)
	ADMA	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	56.1%	8.4%	14.8%	17.7%	11.2%	5.1%	30.2%
Annualized Volatility	59.7%	14.5%	17.1%	15.6%	18.7%	18.9%	48.6%
Sharpe Ratio	0.98	0.40	0.70	0.91	0.48	0.18	0.57
Correlation With Other Assets		27.4%	34.0%	9.6%	5.1%	28.1%	14.2%

Based On 10-Year Data

		Comparison of ADMA With Other Asset Classes (Last 10Y)
	ADMA	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	8.5%	10.1%	15.0%	14.6%	6.9%	5.4%	69.0%
Annualized Volatility	69.1%	16.6%	18.0%	14.8%	17.6%	20.8%	55.8%
Sharpe Ratio	0.42	0.50	0.72	0.82	0.31	0.23	0.89
Correlation With Other Assets		20.5%	24.5%	4.2%	10.2%	19.3%	9.7%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	18,829,424
Short Interest: % Change Since 11302025	1.4%
Average Daily Volume	2,592,477
Days-to-Cover Short Interest	7.26
Basic Shares Quantity	238,602,978
Short % of Basic Shares	7.9%

Returns Analyses

	Title
0	With ADMA Biologics Stock Surging, Have You Considered The Downside?
1	ADMA Biologics Stock Return Comparison
2	[10/1/2021] Adma Biologics Inc Com (ADMA) Stock Price Forecast: AI Forecasts ADMA Stock Price To Be Around $1.22 In A Month (Up 2.2%)
3	ADMA Biologics Total Shareholder Return (TSR): 175.2% in 2022 and -1.0% 3-yr returns (above peer average)

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/5/2025	-8.7%	7.1%	26.2%
8/6/2025	-9.7%	-7.2%	-9.0%
3/3/2025	7.5%	4.9%	22.7%
11/7/2024	14.7%	2.4%	-3.6%
8/8/2024	30.9%	44.3%	50.8%
5/9/2024	27.1%	30.7%	51.2%
2/28/2024	-0.4%	13.8%	22.7%
11/8/2023	5.8%	5.0%	2.5%
...
SUMMARY STATS
# Positive	13	17	14
# Negative	8	4	7
Median Positive	7.5%	7.3%	24.4%
Median Negative	-9.1%	-14.1%	-7.1%
Max Positive	30.9%	44.3%	51.2%
Max Negative	-19.8%	-18.5%	-37.4%

	Forward Returns
11/5/2025	-8.7%	7.1%	26.2%
8/6/2025	-9.7%	-7.2%	-9.0%
3/3/2025	7.5%	4.9%	22.7%
11/7/2024	14.7%	2.4%	-3.6%
8/8/2024	30.9%	44.3%	50.8%
5/9/2024	27.1%	30.7%	51.2%
2/28/2024	-0.4%	13.8%	22.7%
11/8/2023	5.8%	5.0%	2.5%
8/9/2023	6.2%	9.4%	-5.4%
3/23/2023	6.8%	1.6%	10.6%
11/9/2022	27.5%	27.9%	43.7%
8/10/2022	5.2%	15.6%	34.4%
5/11/2022	17.5%	40.6%	35.7%
1/19/2022	3.6%	7.3%	19.7%
11/10/2021	13.6%	7.1%	-5.0%
8/12/2021	-1.3%	-18.5%	-21.9%
5/12/2021	-3.0%	5.4%	9.0%
1/19/2021	6.2%	9.8%	17.9%
11/5/2020	-9.5%	-10.0%	-7.1%
8/5/2020	-19.8%	-18.3%	-37.4%
3/13/2020	-16.7%	4.2%	31.5%
SUMMARY STATS
# Positive	13	17	14
# Negative	8	4	7
Median Positive	7.5%	7.3%	24.4%
Median Negative	-9.1%	-14.1%	-7.1%
Max Positive	30.9%	44.3%	51.2%
Max Negative	-19.8%	-18.5%	-37.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
09/30/2025	11/05/2025	10-Q (09/30/2025)
06/30/2025	08/06/2025	10-Q (06/30/2025)
03/31/2025	05/07/2025	10-Q (03/31/2025)
12/31/2024	03/18/2025	10-K (12/31/2024)
09/30/2024	11/07/2024	10-Q (09/30/2024)
06/30/2024	08/08/2024	10-Q (06/30/2024)
03/31/2024	05/09/2024	10-Q (03/31/2024)
12/31/2023	02/28/2024	10-K (12/31/2023)
09/30/2023	11/08/2023	10-Q (09/30/2023)
06/30/2023	08/09/2023	10-Q (06/30/2023)
03/31/2023	05/10/2023	10-Q (03/31/2023)
12/31/2022	03/23/2023	10-K (12/31/2022)
09/30/2022	11/09/2022	10-Q (09/30/2022)
06/30/2022	08/10/2022	10-Q (06/30/2022)
03/31/2022	05/11/2022	10-Q (03/31/2022)
12/31/2021	03/24/2022	10-K (12/31/2021)

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	ELMS STEVE		6162025	Sell	21.69	92,941	2,015,890	44,068,224	Form
1	Guiheen Lawrence P.		6112025	Sell	20.96	20,000	419,200	1,987,637	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

ADMA Biologics (ADMA)

Market Price (12/29/2025): $19.1 | Market Cap: $4.6 BilSector: Health Care | Industry: Biotechnology

ADMA Biologics (ADMA)

Market Price (12/29/2025): $19.1Market Cap: $4.6 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

ADMA Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About ADMA Biologics (ADMA)

Addressable Markets for ADMA Biologics' Main Products:

Intravenous Immune Globulin (IVIG) Market:

Hyperimmune Globulins Market:

Interactive Breakdown

Better Bets than ADMA Biologics (ADMA)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADMA: 56.9% | 9.3x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADMA: 56.9% | 27.3x)

Higher Rev Chg LTM (Value for ADMA: 27.6%)

Higher Rev Chg 3Y Avg (Value for ADMA: 56.9%)

Higher Op Mgn LTM (Value for ADMA: 34.2%)

Higher CFO/Rev LTM (Value for ADMA: 13.3%)

Higher FCF/Rev LTM (Value for ADMA: 8.3%)

Higher Total Yield (Value for ADMA: 4.6%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADMA: 56.9% | 9.3x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADMA: 56.9% | 27.3x)

Higher Rev Chg LTM (Value for ADMA: 27.6%)

Higher Rev Chg 3Y Avg (Value for ADMA: 56.9%)

Higher Op Mgn LTM (Value for ADMA: 34.2%)

Higher CFO/Rev LTM (Value for ADMA: 13.3%)

Higher FCF/Rev LTM (Value for ADMA: 8.3%)

Higher Total Yield (Value for ADMA: 4.6%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADMA: 56.9% | 9.3x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADMA: 56.9% | 27.3x)

Higher Rev Chg LTM (Value for ADMA: 27.6%)

Higher Rev Chg 3Y Avg (Value for ADMA: 56.9%)

Higher Op Mgn LTM (Value for ADMA: 34.2%)

Higher CFO/Rev LTM (Value for ADMA: 13.3%)

Higher FCF/Rev LTM (Value for ADMA: 8.3%)

Higher Total Yield (Value for ADMA: 4.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for ADMA Biologics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Market Price (12/29/2025): $19.1 | Market Cap: $4.6 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (12/29/2025): $19.1
Market Cap: $4.6 Bil
Sector: Health Care
Industry: Biotechnology